Elanco Animal Health — Third Quarter 2026 Earnings Summary

Elanco Animal Health reported third-quarter 2026 revenue of $1.265 billion, representing an 11% year-over-year increase and 9% organic constant currency growth. The company achieved an adjusted net income of $136 million and an adjusted EBITDA of $243 million, while reducing its net leverage ratio to 2.9 times adjusted EBITDA. Driven by strong performance in Pet Health and global ruminants, Elanco raised its full-year 2026 revenue guidance to between $5.155 billion and $5.18 billion and adjusted EBITDA guidance to between $1.05 billion and $1.065 billion. Key product drivers included Zenrelia and Credelio Quattro, which reached new market share highs, alongside a 4% acceleration in pricing.